Psoriasis is a chronic inflammatory skin disease which affects ~2–3% of the population, making it one of the most prevalent autoimmune diseases worldwide, and can be associated with other inflammatory conditions, such as psoriatic arthritis, inflammatory bowel disease and coronary artery disease.
The skin is the body's primary barrier against outside world, having a unique environment in which skin cells interact with immune cells:
There remains a considerable unmet medical need for a safe and effective treatment for mild to moderate psoriasis. Biologic therapies are being used with more frequency to treat moderate to severe psoriasis, providing the therapeutic advantage of targeting specific pathways that contribute to the inflammatory response.
Glycomar is developing a series of oligosaccharide molecules which target pathways intimately involved in the immune/inflammatory response, coupled with the achievement of target organ selectivity due to local application, should have an optimal therapeutic product profile for treatment of mild to moderate psoriasis.